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A Paper-Based Test for Screening 
Newborns for Sickle Cell Disease
Nathaniel Z. Piety1,*, Alex George2,*, Sonia Serrano3, Maria R. Lanzi3, Palka R. Patel4, 
Maria P. Noli4, Silvina Kahan4, Damian Nirenberg2,4, João F. Camanda5, Gladstone Airewele2 & 
Sergey S. Shevkoplyas1,2
The high cost, complexity and reliance on electricity, specialized equipment and supplies associated 
with conventional diagnostic methods limit the scope and sustainability of newborn screening for 
sickle cell disease (SCD) in sub-Saharan Africa and other resource-limited areas worldwide. Here we 
describe the development of a simple, low-cost, rapid, equipment- and electricity-free paper-based 
test capable of detecting sickle hemoglobin (HbS) in newborn blood samples with a limit of detection 
of 2% HbS. We validated this newborn paper-based test in a cohort of 159 newborns at an obstetric 
hospital in Cabinda, Angola. Newborn screening results using the paper-based test were compared to 
conventional isoelectric focusing (IEF). The test detected the presence of HbS with 81.8% sensitivity 
and 83.3% specificity, and identified SCD newborns with 100.0% sensitivity and 70.7% specificity. The 
use of the paper-based test in a two-stage newborn screening process could have excluded about 70% 
of all newborns from expensive confirmatory testing by IEF, without missing any of the SCD newborns 
in the studied cohort. This study demonstrates the potential utility of the newborn paper-based test for 
reducing the overall cost of screening newborns for SCD and thus increasing the practicality of universal 
newborn SCD screening programs in resource-limited settings.
Universal newborn screening, in combination with early intervention for affected infants, has nearly eliminated 
early childhood mortality due to sickle cell disease (SCD; HbSS) in high-income developed countries1–3. In con-
trast, a majority of children born with SCD in low-income developing countries die before the age of 5 due to 
lack of early diagnosis and comprehensive care4,5. Recent estimates suggest that implementation of wide-spread 
screening and follow-up care in countries affected most by the disease (e.g. Nigeria, Democratic Republic of the 
Congo, India) could save the lives of nearly 10 million children by 20506. Data from pilot screening and treat-
ment programs in sub-Saharan Africa demonstrate > 95% survival for affected infants enrolled in inexpensive 
follow-up care, such as penicillin prophylaxis, pneumococcal immunizations, malaria bed nets, and family edu-
cation about the disease7.
The major barriers limiting the expansion of these highly successful pilot screening programs are the high cost 
and technical complexity of conventional diagnostics methods (e.g. HPLC, high-performance liquid chroma-
tography8, or IEF, isoelectric focusing electrophoresis9), and their dependence on specialized equipment, stable 
infrastructure and well-trained laboratory personnel4,5,10. Because of these limitations, newborn screening for 
SCD remains confined to only a few specialized clinical laboratories in major population centers, almost entirely 
missing the majority of all births occurring out of hospital7,11,12. Importantly, the results of screening with conven-
tional laboratory methods are rarely available before postnatal discharge, reducing the all-important follow-up 
rate to as low as 50% of identified newborns7,11. There is therefore an urgent need for a screening test that is suf-
ficiently inexpensive, portable, simple and rapid enough to enable universal screening of newborns for SCD in 
resource-limited settings lacking established infrastructure, specialized equipment or trained personnel.
We have previously described the development and clinical validation of a rapid, low-cost paper-based diag-
nostic test for SCD that permits the diagnosis of adults and children older than 6 months of age13–15. We now 
describe a test based on the same principles which is optimized to detect the low levels of sickle hemoglobin 
(HbS) present in the blood of newborns, allowing the direct screening of newborns for SCD and sickle cell trait 
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(SCT; HbAS). We also report on the feasibility and diagnostic accuracy of the paper-based newborn test as per-
formed by local health workers in a resource-limited clinical setting in Cabinda, Angola.
Results
Design and operation of the paper-based newborn screening test. The design and operation of a 
paper-based SCD test capable of diagnosing SCD in adults and children older than 6 months have been described 
previously in detail (Fig. 1a)13–15. When evaluated visually, the limit of detection (LOD) for the adult test was 
about 15% HbS15, which was insufficient for detecting the very low percentages of HbS typically found in new-
born samples − 6.5 ± 2.8% for SCT (HbFAS) and 10.2 ± 3.9% for SCD (HbFS)16. The reason for the relatively high 
LOD was the faint center spot in the center of the stain formed by cellular debris of lysed red blood cells even in 
the complete absence of any HbS (Fig. 1b, inset)14.
To address this limitation and further lower the LOD of the test, we introduced a filtration step for removing 
cellular debris from the blood lysate prior to deoxygenation (Fig. 2a). This newborn paper-based test is per-
formed by first mixing 40 μ L of blood with 200 μ L of lysis buffer (8 g/L saponin in phosphate buffer) in the bottom 
chamber of a disposable syringe-less filter (0.2 μ m PES Whatman Mini-Uniprep™ , GE Healthcare, USA). After 
5 minutes, the filter top is compressed until the solution is filtered into the top chamber. An approximately equal 
volume (75 μ L) of the deoxygenation buffer (200 g/L sodium hydrosulfite in phosphate buffer) is then added to 
the top chamber and mixed with the filtered solution. After 10 minutes, a 20 μ L drop of the mixture is deposited 
onto chromatography paper (Whatman™ 1 Chr, GE Healthcare, USA) and allowed to dry for up to 25 minutes 
(Fig. 2a). The characteristic bloodstain pattern, indicative of the presence or absence of HbS in the blood sample, 
is formed by polymerized deoxy-HbS, which becomes trapped in the pores of the chromatography paper sub-
strate in the area where the drop was deposited, and soluble forms of hemoglobin which wick laterally through 
the pores of the paper towards the periphery. The inherent red color of hemoglobin is sufficient for visual evalua-
tion of the bloodstain pattern, with no additional signal amplification necessary.
Figure 2b shows characteristic bloodstain patterns for artificially reconstituted samples with 0, 1, 2, 3, 4, 5, 
10, 25 and 50% HbS that were used to determine the LOD of the newborn test. Novice scorers (n = 5) with no 
previous experience performing or evaluating the test were provided with reference images of bloodstain patterns 
formed by samples with and without HbS and asked to score a set of stains (n = 45) as positive or negative for 
the presence of HbS. All users correctly scored all stains with > 1% HbS as HbS-positive (LOD = 2% HbS). The 
test was independently performed 5 times for each sample in order to determine reliability of visual scoring. All 
users made the same diagnosis for all 5 tests at every HbS concentration, indicating that visual scoring of the test 
Figure 1. Previously developed paper-based SCD diagnostic test for adults and children older than 6 
months of age. (a) Schematic illustration of the steps required to perform the adult paper-based test: (i) 20 μ L  
of whole blood collected via finger-stick (or venipuncture) is added to the plastic tube; (ii) the blood is 
mixed with 200 μ L of hemoglobin solubility buffer (phosphate buffer, saponin and sodium hydrosulfite); (iii) 
after 10 minutes, a 20 μ L drop of the mixture is deposited on chromatography paper and allowed to dry for 
25 minutes. (b) Representative bloodstains for samples with less than 30% sickle hemoglobin (HbS) produced 
by the adult paper-based test. Cellular debris remaining after RBC lysis create a faint center spot even for 
samples with 0% HbS, reducing the limit of detection (LOD; dashed line) for this version of the paper-based to 
~15% HbS. Typical adult HbS ranges for different genotypes are marked above the stains.
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is highly reliable. The scoring process was also repeated 3 times for the same bloodstains (presentation order ran-
domized) and scores were perfectly consistent between trials, further supporting that the visual scoring of the test 
is highly repeatable. The Fleiss’ kappa value over all scored stains was 1.0, suggesting a perfect agreement between 
all five scorers in interpreting the set of bloodstain patterns.
Clinical validation of the newborn paper-based screening test in a resource-limited setting. 
To evaluate the performance of the newborn paper-based screening test in the real-world environment of 
a resource-limited clinical setting, we deployed the test at the pilot newborn screening program in Cabinda, 
Angola. The rationale for this field testing was that newborn screening with the paper-based test should identify 
all samples positive for HbS (i.e. from both SCD and SCT newborns) and should therefore capture all newborns 
at risk for either disease or trait for confirmatory IEF testing. We trained local health workers to collect capillary 
blood samples from newborns via heel-stick, process the samples using the paper-based test, and score the result 
of the test visually as either HbS-positive or HbS-negative (Fig. 3a). The results of paper-based testing were then 
compared with those of IEF testing performed on the same samples as part of the current standard screening 
practice7.
Figure 3b shows the confusion matrix for the paper-based test performed by the local health workers on 
samples from 159 newborns with unknown SCD status. The test was able to identify HbS-positive samples with a 
sensitivity of 81.8% (95% confidence interval: 75.1–87.0%), specificity of 83.3% (CI: 76.8–88.3%), positive predic-
tive value of 56.3% (CI: 48.5–63.7%), negative predictive value of 94.6% (CI: 89.9–97.2%) and overall diagnostic 
accuracy of 83.0% (CI: 76.4–88.1%). The relatively high number of false-positives for the newborn test – samples 
from normal (HbFA) newborns misidentified as HbS-positive – was due to occasional filter malfunction result-
ing in incomplete removal of cellular debris from the whole blood lysate, thus allowing the formation of a faint 
center spot which was misinterpreted as HbS-positive. All of the false HbS-negatives (4%) for the newborn test 
(i.e. samples containing some HbS misidentified as HbS-negative) were from SCT (HbFAS) newborns (Fig. 3b). 
Importantly, the newborn paper-based test was able to identify SCD (HbFS) newborns with a sensitivity of 
100.0% (CI: 97.6–100.0%), specificity of 70.7% (CI: 63.2–77.2%), positive predictive value of 4.2% (CI: 2.0–8.5%), 
negative predictive value of 100.0% (CI: 97.6–100.0%) and overall diagnostic accuracy of 71.1% (CI: 63.6–77.6%).
The paper-based test deployed in Angola employed a reusable pipette with disposable pipette tips (4 per 
test) for liquid metering. The cost per test for all test specific consumables (i.e., chromatography paper, reagents, 
syringeless filter, tubes and pipette tips) of the paper-based test deployed in Angola was $2.16 (for a detailed cost 
breakdown please see Supplementary Table 1). Figure 4 shows a self-contained, distributable version of the test kit 
comprised of off-the-shelf components, with about the same cost per test. For the self-contained test kit, the reus-
able pipette with disposable tips was replaced with disposable plastic pipettes and droppers. The total cost per test 
Figure 2. Paper-based newborn SCD screening test. (a) Schematic illustration of the steps required to 
perform the newborn paper-based test: (i) 20 μ L of whole blood collected via heel-stick is added to the bottom 
chamber of the syringeless filter; (ii) the blood is mixed with lysis buffer (phosphate buffer and saponin); (iii) 
after 5 min the top of the syringeless filter is inserted into the bottom and compressed to filter out cellular debris; 
(iv) deoxygenation buffer (phosphate buffer and sodium hydrosulfite) is added to the filtered solution; (v) after 
10 min a 20 μ L drop of the mixture is deposited on chromatography paper and allowed to dry for 25 minutes. 
All steps required to perform the test can be completed within 40 min. Test results can also be read out visually, 
immediately after the formation of the blood stain. (b) Representative bloodstains produced on paper by the 
paper-based newborn SCD screening test for blood samples with various sickle hemoglobin (HbS) levels. The 
limit of detection (LOD; dashed line) for detecting the presence of any HbS in a blood sample visually was 2%. 
Typical newborn HbS ranges for different genotypes are marked below the stains.
www.nature.com/scientificreports/
4Scientific RepoRts | 7:45488 | DOI: 10.1038/srep45488
kit comprised of off-the-shelf materials is $2.12 (for a detailed cost breakdown please see Supplementary Table 2). 
The retail-priced syringeless filter and disposable plastic components constitute the majority of test cost (reagents 
and chromatography paper cost < $0.07 per test), and as such the per test cost can be expected to decrease signif-
icantly if the test kits are produced in large quantities using non-marked-up plastic components. The per test cost 
estimates for both versions of the paper-based newborn SCD screening test do not include the cost of consuma-
bles which would be common to any blood test (e.g. gloves, alcohol swab, lancet, collection tube and bandage), as 
these materials are not typically included in retail test kits.
Table 1 shows the potential cost savings from using the paper-based test as a preliminary screen-in test prior 
to confirmatory IEF testing of positive samples, based on the previously published cost per sample of $4.94 for 
IEF in Angola7. For our cohort of 159 newborns, screening all samples by IEF alone would cost $785.46 (cost per 
sample = $4.94). In contrast, screening using the paper-based test followed by IEF testing only of positive samples 
would cost an estimated $343.44 for the paper-based testing and $237.12 for subsequent IEF testing of positive 
samples, for a total cost of $580.56 (cost per sample = $3.65); a potential cost reduction of 29%. The relatively low 
incidence of SCD and SCT in the general population and consequently the relatively low ratio of confirmatory 
IEF to paper-based screening tests which will need to be performed, suggest that the potential cost savings from 
such a two-stage, screen-in program would increase proportionally with the number of newborns screened.
Figure 3. Accuracy of the paper-based newborn SCD screening test. (a) Representative bloodstains 
produced on paper by HbS-positive and HbS-negative newborn samples. (b) Confusion matrix of the results of 
tests performed and interpreted by local health workers at the newborn screening laboratory of the Clinica de 
Celulas Falciformes at the Dispensario Materno Infantil (Cabinda, Angola). Shaded cells contain numbers of 
correctly screened newborns (i.e. true HbS-positives and true HbS-negatives).
Figure 4. Self-contained, distributable version of the paper-based SCD newborn screening test kit, 
comprised of off-the-shelf components. The kit consists of one exact volume pipette for blood collection, two 
tubes containing lysis and deoxygenation buffers respectively, one syringeless filter, one dropper for depositing 
the mixture on paper, and one patterned piece of chromatography paper. Ten cent U.S. coin shown for size 
reference (17.9 mm diameter).
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Discussion
Two major barriers to successful implementation of universal newborn screening for SCD in low-income devel-
oping countries are the cost and logistical complexity of conventional diagnostic methods and the delayed availa-
bility of screening results17. In Angola, for example, the cost of newborn screening using IEF is reported as $4.94 
per sample, and as a result screening remains limited to only the major urban centers of Luanda and Cabinda 
City7. The need to transport blood samples from birthing centers to a centralized testing laboratory for analysis 
also severely limits the ability to screen children at remote and rural facilities. In Angola, the results of IEF testing 
are rarely available less than 4 weeks after sample collection, and as a consequence, fewer than 55% of newborns 
with SCD identified through the IEF-based screening in Angola are successfully re-contacted and initiated on 
prophylaxis regimens7.
The current paradigm of universal newborn screening is to test every child for SCD at birth using a 
highly-accurate laboratory method such as IEF18. Given the relatively low incidence of SCD in the general popu-
lation, most of the resources of such a screening paradigm are currently spent on diagnosing healthy children. A 
more cost-effective alternative could be to first identify newborns at the highest risk for having SCD using a rapid 
and low-cost screening test with a low false-negative rate, and then perform higher-cost confirmatory testing only 
for these screened-in high-risk newborns.
The paper-based SCD newborn screening test described here successfully addresses many of the techni-
cal and logistical impediments of the conventional approaches described above. Firstly, the per test cost of the 
self-contained, distributable paper-based test using off-the-shelf components purchased at retail prices is $2.12, 
already less than half the per test cost of conventional IEF currently employed in the pilot newborn screening 
program in Angola ($4.94 per sample). Additionally, the per test cost of the finalized test kit could potentially 
be lower than the current version as it will employ integrated sample collection and processing components, 
produced by a contract manufacturing partner, which are projected to be less expensive than the sum of the cur-
rent retail prices for the multiple commercially available components comprising the current test. Secondly, the 
paper-based test is lightweight, completely electricity-free, requires no specialized equipment or instrumentation 
and is simple enough for a user with no previous experience performing the test to learn to operate and interpret 
the test with expert proficiency in under one hour. Therefore the paper-based test would not be limited to cen-
tralized laboratories with specialized equipment and trained technicians, but rather could be deployed to remote 
facilities and operated by health workers with any level of experience. In this study the results of the test were typi-
cally available within one hour or less of initiating the test. This rapid turnaround time, compared to conventional 
laboratory methods, could therefore potentially enable counseling of families with high-risk newborns before 
postpartum discharge (usually within 6–12 hours of delivery at the Primero de Maio obstetric center). Finally, our 
data show that a two-stage approach consisting of preliminary screening of all infants and confirmatory testing of 
only the high-risk subset could reduce the number of newborns requiring IEF testing by at least 70%, thus signif-
icantly reducing the overall cost of the screening program. More importantly, accurate identification of newborns 
at the highest risk for SCD could help focus limited available resources on establishing proper longitudinal care 
for this much smaller cohort.
The paper-based test offers important advantages over existing technologies designed to enable low-cost SCD 
diagnostics in resource-limited settings. Conventional hemoglobin solubility tests (e.g. SickleDexTM) are not sen-
sitive enough to detect the low levels of HbS typically found in newborn blood samples, are notoriously difficult 
to standardize and interpret, and are confounded by numerous comorbidities which effect the turbidity of blood 
samples19. Various modifications of conventional laboratory methods (e.g., lower-cost implementation of IEF20, 
or a microfluidics-based HE21) as well as novel diagnostic approaches (e.g., density-based separation of sickle 
RBCs in capillaries22,23, or magnetic levitation-based smartphone platforms24) may reduce the cost of testing and/
or may be performed at the point-of-care but continue to require highly trained personnel and rely on complex 
specialized equipment and electricity to operate. Rapid diagnostic tests for SCD based on conventional lateral 
flow immunoassay technology are instrument- and electricity-free and show great potential25–27. However, these 
tests still require extensive field-testing to determine real-world performance for newborn samples and for tests 
performed in resource-limited settings, and are subject to well-known limitations of all antibody-based assays, 
such as limited shelf-lives when ambient temperatures exceed recommended ranges for even short periods of 
time during shipping, storage or usage – a scenario which is highly likely in resource-limited setting such as 
sub-Saharan Africa28. Additionally, because these tests rely on proprietary antibodies, their cost per test may not 
IEF alone Paper-based test + IEF
Cohort size 159 159
Number screened by paper-based test 0 159
Total cost of paper-based screening (at $2.16/test) $0 $343.44
Number requiring IEF testing 159 48
Total cost of IEF testing (at $4.94/test) $785.46 $237.12
Total cost of all testing $785.46 $580.56
Average cost per sample $4.94 $3.65
Table 1.  Potential cost savings from using the paper-based SCD newborn screening test as a preliminary 
screen, followed by confirmatory diagnosis of only screened-in HbS-positive newborns via isoelectric 
focusing (IEF).
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be significantly lower than the cost of conventional testing methods such as IEF, and the rates and scale at which 
these tests can be manufactured may be limited by the rates at which the proprietary antibodies can be produced.
There are three major limitations to the paper-based newborn SCD screening test. The first is that the 
paper-based test cannot yet distinguish between SCT and SCD in newborns, and therefore must be used as a 
screening, rather than a diagnostic test. To make a definitive diagnosis, the screening results must be confirmed 
with a laboratory test (such as IEF) or later in life using the previously developed adult version of the paper-based 
test13,15. The second limitation is the relatively high incidence of false-positives observed in this study. This prob-
lem was due to the occasional malfunction of the filter used to remove cellular debris from the blood lysate, 
resulting in a false central spot mimicking that produced by HbS. The volume of blood and lysis buffer used in the 
filtration step has since been decreased in order to reduce the rate of false-positive results due to filter malfunction 
(please see Supplementary Information). Finally, we had a small but significant rate of false-negative results (4%) 
with the paper-based test, all of which were from newborns with SCT. A retrospective analysis of these samples 
and bloodstains revealed that the blood samples had clotted before processing or were otherwise inadequate, 
suggesting that these false-negatives were due to improper sample handling, rather than a malfunction of the 
paper-based test itself. Quality control standards for blood samples to be used with the paper-based test and 
obligate IEF analysis of samples deemed inadequate for the paper-based test could prevent these false negatives in 
further iterations of this two-stage testing protocol.
In summary, we demonstrate that the paper-based newborn SCD screening test, optimized to detect the low 
levels of sickle hemoglobin present in newborn blood, enables the direct screening of newborns for sickle cell 
trait and sickle cell disease. We also demonstrate that this test is feasible and has a high diagnostic accuracy when 
performed by local health workers in a resource-limited clinical setting. These results demonstrate the potential 
utility of the newborn paper-based test for identifying high-risk newborns in the immediate postnatal period 
and reducing the overall cost of screening newborns for sickle cell disease, thus increasing the practicality and 
effectiveness of universal newborn SCD screening programs in resource-limited settings.
Methods
Study design and participants. All experimental protocols involving human blood samples were 
approved by the institutional review boards at the Universidade Onze de Novembro Medical School (Cabinda, 
Angola), Baylor College of Medicine (Houston, USA) and University of Houston (Houston, USA). Informed 
consent was obtained from all subjects. All experiments were performed in accordance with guidelines and reg-
ulations established by the University of Houston, Baylor College of Medicine and the U.S. Department of Health 
and Human Services for the protection of human study subjects. After obtaining informed consent from the 
newborns’ mothers, local health workers collected blood samples from newborns at the obstetric center of the 
Primero de Maio hospital in Cabinda. Eligibility criteria included gestation of greater than 30 weeks and uncom-
plicated delivery (judged by local clinical staff). Samples were collected from n = 160 newborns, a convenience 
sample. We successfully screened 160 newborn samples with the paper-based test, and performed successful IEF 
testing on 159 of these samples (Fig. 5).
Blood sample collection, storage, and processing. For initial development of the paper-based 
newborn SCD screening test, blood samples were collected from SCD (HbSS) patients at the Texas Children’s 
Hematology Center and from healthy volunteers (HbAA) into Vacutainer vials (K2EDTA, BD Diagnostics, USA) 
using standard venipuncture technique. Samples were stored at 4 °C until use. Artificially reconstituted samples 
Figure 5. Classification flowchart for newborn samples evaluated with the paper-based SCD newborn 
screening test and isoelectric focusing (IEF).
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with a range of HbS levels were created by mixing ABO/Rh-matched, equal-hematocrit HbAA and HbSS blood 
samples at various ratios.
For test validation in Cabinda, blood samples were collected from newborns by heel-stick onto blood col-
lection cards (Whatman 903 Protein Saver Card, GE Healthcare, USA) and into capillary blood collection tubes 
(Microvette, K2EDTA, Sarstedt AG & Co, Germany). Eluted dried blood spot samples were tested with isoelec-
tric focusing (IEF) following existing standard operating procedures7. Liquid blood samples were refrigerated 
and used to perform the paper-based test within 7 days of collection. For all patients, the paper-based test was 
completed before IEF analysis. Local health workers interpreted the results of the paper-based test visually, using 
reference images of HbS-positive and HbS-negative bloodstains.
Statistical analysis. Mean, standard deviation, p-values, and confusion matrices were calculated 
using built-in functions in MATLAB 2014b (The Math Works Inc., Natick, MA). 95% confidence inter-
vals (CI) were calculated using the Wilson method29. Fleiss’ kappa calculations were performed to determine 
inter-operator agreement for visual scoring of bloodstains30. Performance metrics were calculated as: sensitiv-
ity = TP/(TP + FN); specificity = TN/(FP + TN); positive predictive value = TP/(TP + FP); negative predictive 
value = TN/(TN + FN); and accuracy = (TP + TN)/(TP + FP + TN + FN); where TP = true positive, FP = false 
positive, TN = true negative and FN = false negative.
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